SMO ClinPlusLTD Future Growth
Future criteria checks 2/6
SMO ClinPlusLTD is forecast to grow earnings and revenue by 18.7% and 15.4% per annum respectively. EPS is expected to grow by 18.2% per annum. Return on equity is forecast to be 13.7% in 3 years.
Key information
18.7%
Earnings growth rate
18.2%
EPS growth rate
Life Sciences earnings growth | 28.1% |
Revenue growth rate | 15.4% |
Future return on equity | 13.7% |
Analyst coverage | Low |
Last updated | 20 May 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,210 | 225 | N/A | 189 | 1 |
12/31/2025 | 1,064 | 193 | N/A | 165 | 1 |
12/31/2024 | 912 | 162 | N/A | 120 | 1 |
3/31/2024 | 787 | 132 | 76 | 89 | N/A |
12/31/2023 | 760 | 135 | 105 | 115 | N/A |
9/30/2023 | 729 | 135 | 128 | 138 | N/A |
6/30/2023 | 690 | 115 | 146 | 158 | N/A |
3/31/2023 | 621 | 88 | 79 | 87 | N/A |
1/1/2023 | 586 | 72 | 32 | 40 | N/A |
9/30/2022 | 542 | 52 | 37 | 49 | N/A |
6/30/2022 | 523 | 50 | -30 | -26 | N/A |
3/31/2022 | 528 | 58 | 12 | 17 | N/A |
12/31/2021 | 503 | 58 | 37 | 42 | N/A |
9/30/2021 | 472 | 58 | 2 | 6 | N/A |
6/30/2021 | 421 | 53 | 31 | 35 | N/A |
3/31/2021 | 373 | 46 | 22 | 26 | N/A |
12/31/2020 | 335 | 35 | 18 | 22 | N/A |
12/31/2019 | 304 | 52 | 41 | 46 | N/A |
12/31/2018 | 193 | 30 | 21 | 23 | N/A |
9/30/2018 | 172 | 29 | 22 | 24 | N/A |
6/30/2018 | 147 | 26 | 23 | 26 | N/A |
3/31/2018 | 132 | 23 | 25 | 28 | N/A |
12/31/2017 | 116 | 20 | N/A | 29 | N/A |
9/30/2017 | 98 | 14 | N/A | 20 | N/A |
6/30/2017 | 80 | 9 | N/A | 12 | N/A |
3/31/2017 | 72 | 8 | N/A | 6 | N/A |
12/31/2016 | 63 | 8 | N/A | -1 | N/A |
12/31/2015 | 42 | -14 | N/A | 8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301257's forecast earnings growth (18.7% per year) is above the savings rate (2.9%).
Earnings vs Market: 301257's earnings (18.7% per year) are forecast to grow slower than the CN market (22.2% per year).
High Growth Earnings: 301257's earnings are forecast to grow, but not significantly.
Revenue vs Market: 301257's revenue (15.4% per year) is forecast to grow faster than the CN market (13.7% per year).
High Growth Revenue: 301257's revenue (15.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 301257's Return on Equity is forecast to be low in 3 years time (13.7%).